Library / Peptides / Recovery & Healing / BPC-157
Emerging evidence · Grade B

BPC-157

BPC-157 (Body Protection Compound-157)
Score
70 / 100
Half-life
Short (minutes)
Class
Body-protection peptide
Status
Investigational
TL;DR
01
A 15-amino-acid peptide derived from a protein in gastric juice, marketed heavily for tendon, muscle, gut, and 'systemic' healing.
02
Its reputation rests on an unusually large animal literature — hundreds of rat studies showing accelerated healing across many tissues — but there are no published human efficacy trials.
03
Most of that evidence comes from a single research group, which limits how much independent confirmation there is.
04
It is not approved anywhere; the FDA has flagged it over compounding-safety concerns, and consumer supply is research-grade or compounded with no purity guarantee.
05
It appears well tolerated in animals and anecdotally, but its long-term human safety — including the theoretical risk that pro-healing, pro-angiogenic signaling could also feed abnormal tissue — is simply unstudied.
Human efficacy RCTs
None published
healing claims are preclinical
Preclinical studies
Hundreds
predominantly rat models
Evidence source
~1 group
concentrated, limited replication
Regulatory
Flagged by FDA
compounding-safety concerns
Approval
None
research/compounded only
Part 01 · How it works

Mechanism.

BPC-157 is a fragment of a 'body protection compound' found in stomach fluid. In animals it appears to speed healing across a striking range of tissues — tendon, muscle, nerve, gut lining, blood vessels — seemingly by promoting the growth of new blood vessels and the migration of repair cells, and by stabilizing pathways that protect tissue under stress. The mechanism is plausible and the animal results are consistent, but 'works in rats across many models' is not the same as 'proven to help people,' and that human step has not been taken.

Think of it as a general-purpose repair signal that, in animals, seems to tell many different tissues to heal faster. Whether that same signal does the same job in humans is the untested question.

Angiogenesis / cell migration
In animal and cell models, promotes new blood-vessel formation and migration of fibroblasts and other repair cells (e.g., FAK-paxillin activation in tendon fibroblasts).
Cytoprotection
Described as a mediator of Robert's cytoprotection — stabilizing gastrointestinal and other tissue against injury (e.g., NSAID damage) in rodents.
Nitric-oxide & growth-factor pathways
Proposed interactions with the NO system and growth-factor signaling underlie its broad healing profile in preclinical work.
Evidence stage
Extensive preclinical (mostly rat) data; no published human efficacy trials.
Part 02 · Dosing & administration

How it's taken.

Community-reported · unregulated

Values below reflect commonly reported community protocols for BPC-157. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
250-500 mcg
Subcutaneous injection (oral capsule for GI use) · 1-2x daily
Duration
8 weeks on / 8 weeks off
·
Community injection protocols cluster at ~500 mcg/day (often split 250 mcg AM/PM), typically with no loading phase.
·
Animal healing studies dosed ~10 µg/kg (intraperitoneal or in drinking water; Cerovecki 2010) — the human microgram figure is a community convention, not a translated animal dose.
·
No FDA-approved dose or human efficacy trial exists; injectable and oral research products carry no purity/identity guarantee.
Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Common
Injection-site reactions
Anecdotal; no controlled incidence data.
Reported
Fatigue / lightheadedness
User-reported; not characterized in trials.
Anecdotal
GI upset (oral)
Reported with oral use; uncharacterized.
Anecdotal
Serious · rare
Long-term human safety
No human safety dataset of any duration exists.
Unknown
Pro-angiogenic / tumor concern
Signals that promote healing and blood-vessel growth could theoretically feed abnormal tissue; unstudied in humans.
Theoretical
Product-quality risk
Research-chemical/compounded supply may not match labeled purity or dose.
Source-dependent
Absolute · do not use
×
Active cancer or history of cancer (may promote angiogenesis)
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to BPC-157 or any component
Relative · discuss first
!
Active or prior cancer — pro-angiogenic mechanism, theoretical concern
!
Pregnancy or breastfeeding — no data
!
Competitive athletes — monitored/prohibited in some anti-doping contexts
!
Anyone expecting proven human benefit — human efficacy has not been demonstrated
Interactions
Anticoagulants (warfarin, heparin)
BPC-157 may affect platelet aggregation and wound healing pathways, potentially altering bleeding risk
Moderate
NSAIDs (ibuprofen, naproxen)
May have additive inflammation-modulating effects; monitor GI symptoms
Minor
Immunosuppressants
BPC-157 modulates immune function which may interfere with immunosuppressive therapy
Moderate
Dopaminergic medications (L-DOPA, dopamine agonists)
BPC-157 influences dopamine system; may potentiate or interfere with dopaminergic drugs
Moderate
Labs to monitor
CBC with Differential
Baseline and monthly
Monitor for blood count changes
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CRP / ESR
Baseline and monthly
Track inflammatory markers
Coagulation Panel (PT/INR)
Baseline
BPC-157 may affect angiogenesis and blood vessel formation
Part 04 · Evidence

How strong is the evidence?

70
Grade B
Grade B, Emerging — but read the axes. BPC-157 has an unusually deep and consistent preclinical record, which is real and is why the score isn't lower. What it does not have is any published human efficacy trial, and its evidence is concentrated in one research group. The number reflects promise, not proof.
Mechanistic plausibility
Coherent pro-healing/angiogenic mechanisms, consistent across many animal injury models.
78
Preclinical breadth
One of the largest animal literatures of any research peptide — many tissues, reproducible direction of effect.
85
Human evidence
No published human efficacy RCTs. Early IBD trials (PL 14736) were reported by the developer but never published as positive efficacy trials or advanced to approval.
38
Safety & tolerability
Very low toxicity in animals and benign anecdotally; long-term human safety unstudied.
72
Independence
Most pivotal work comes from a single group; independent replication is limited.
48
Part 05 · Research log

Every study we cite.

We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.

01
2010
J Appl Physiol Flagged
BPC 157 promotes tendon-fibroblast outgrowth, survival, and migration
Accelerated fibroblast outgrowth and migration and improved cell survival under oxidative stress, via FAK-paxillin activation — a cell/tissue-level mechanism, not a clinical outcome.
In vitro / rat tendon explant · Mechanistic animal/cell study; does not establish human effect.
PMID 21030672 ↗
Moderate (preclinical)
02
2009
Regulatory Peptides Flagged
BPC 157 in traumatic (sciatic) nerve injury
Faster axonal regeneration and improved functional recovery (EMG, walking index) vs control in rats.
Rat sciatic-nerve transection model · Rat model from the primary BPC-157 research group.
PMID 19903499 ↗
Moderate (preclinical)
03
2013
Curr Pharm Des Flagged
BPC 157 as a counter-agent to NSAID toxicity (review)
Summarizes broad protective effects across organs in animal models and references early human IBD safety trials (PL 14736); no published human efficacy RCT is presented.
Narrative review by the developing group · Authored by the primary BPC-157 group; claims of human trials are not accompanied by published efficacy data.
PMID 22950504 ↗
Low (review, conflicted)
Evidence against

What didn't work, and where the evidence is thin.

Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.

01
No published human efficacy trials — the healing claims are all preclinical
Mechanism limit
Curr Pharm Des · 2013
Every headline healing result for BPC-157 comes from animal or cell studies. The only human trials ever referenced (early IBD studies, PL 14736) were reported by the developing group and never published as positive efficacy RCTs or advanced toward approval.
What this means: Buying BPC-157 for a tendon, muscle, or gut problem means acting on rat data. The human evidence that would tell you whether it works — and at what dose — does not exist.
PMID 22950504 ↗
02
Evidence concentrated in a single research group
Mechanism limit
Curr Pharm Des · 2013
The great majority of BPC-157 studies originate from one laboratory. Broad independent replication — the normal check on a striking result — is limited.
What this means: A large literature from a single source is weaker than a smaller one confirmed by many. The consistency is encouraging but not a substitute for independent human data.
PMID 22950504 ↗
Part 06 · Cost & access

Where it's available, at what price.

United States
Not approved
Not an approved drug; the FDA has flagged BPC-157 over compounding-safety concerns. Sold as a research chemical or compounded — no legal consumer medicine.
Grey-market/compounded; unregulated
European Union
Not approved
No approved product.
N/A
United Kingdom
Not approved
No approved product.
N/A
Canada
Not approved
No approved product.
N/A
The Peptide Column takes no affiliate commission from any source. BPC-157 is not approved as a medicine anywhere and the FDA has raised compounding-safety concerns; material sold to individuals is research-grade or compounded, unregulated for human use, and its benefits are unproven in people. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment

Questions to bring.

01
Are there any active clinical trials of BPC-157 I might qualify for given my injury or gut condition?
02
Is there a risk that BPC-157's pro-angiogenic effects could promote growth of existing or undetected tumors?
03
What form of BPC-157 (injectable vs. oral) is most appropriate for my specific use case?
04
How does BPC-157 interact with NSAIDs, corticosteroids, or other medications I take?
References

Every citation, numbered.

Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.

  1. 01.
    BPC 157 promotes tendon-fibroblast outgrowth, survival, and migration · J Appl Physiol, 2010 · PMID 21030672 ↗
  2. 02.
    BPC 157 in traumatic (sciatic) nerve injury · Regulatory Peptides, 2009 · PMID 19903499 ↗
  3. 03.
    BPC 157 as a counter-agent to NSAID toxicity (review) · Curr Pharm Des, 2013 · PMID 22950504 ↗
  4. 04.
    FDA. BPC-157 compounding-safety flag / bulk-substance review · Source ↗